Compare Gemini Space Station Inc (GEMI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Merck & Co., Inc. — how do they compare? Gemini Space Station Inc trades at $4.58 (market cap $590.44M), while Merck & Co., Inc. trades at $128.41 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 517.1× Gemini Space Station Inc's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| GEMI | MRK | |
|---|---|---|
Market Cap | $590.44M | $305.29B |
Sector | Technology | Health |
52-Week High | $32.52 | $129.52 |
52-Week Low | $3.91 | $77.60 |
Enterprise Value | $580.43M | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.69, up 8.06% in the past 24 hours, with a bullish technical signal but weak fundamentals. The company reported a net loss of $582.81 million in 2025 on $179.57 million revenue, with negative profit margins and cash burn from operations. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May-July 2026.
Outlook remains challenged by persistent losses and legal risks, though analyst consensus suggests modest upside to a $5.88 price target. Investment opportunity hinges on execution turnaround, but high operational and litigation risks warrant caution for stock investors.
Merck (MRK) trades at $128.00, up 5.96% on the day. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal robust profitability with a 73.91% gross margin and consistent earnings beats in recent quarters. The company is actively expanding its oncology pipeline through acquisitions, most notably the $6.7 billion tender offer for Terns Pharmaceuticals announced in April 2026.
The outlook is positive, supported by strong analyst consensus (67.57% Buy rating) and a price target implying ~7% upside. Key opportunities include pipeline expansion via M&A and solid cash flow generation. Primary risks involve integration of large acquisitions, patent cliffs for key drugs, and intense competition in the oncology space, which could pressure future growth margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
